Kopran Limited operates in the Medicinals and botanicals sector. Kopran Limited is an India-based company. The principal activities consist of import and export of chemical materials. The Company is engaged primarily in pharmaceuticals business and operates in a single segment. The Company manufactures both active pharmaceutical ingredients (API) and finished dosage forms. Under finished dosage forms, it covers a range of more than 100 dosage forms, including tablets, capsules, dry powder, suspension and injectables. It also provides a range of specialty products which include macrolides and cardiovascular. Its products under finished dosage forms include antibiotics, cardiovascular, anti-diabetes, respiratory/anti-asthmatics, gastrointestinal, pain management, anti-malarial, anthelmentics, antiprotozoals, anti-allergic and erectile dysfunction. Its products under API include cephalosporins, cephalosporins, cardiovascular, macrolides and neuromodulator. Its wholly owned subsidiaries include Kopran Research Laboratories Ltd. and Kopran (H.K) Ltd. In our complete report available for purchase the company is compared to: Albert David Limited, Sms Pharmaceuticals Limited and Shilpa Medicare Limited.